In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen’s autologous NK cell therapy, troculeucel, in Japan.
NKGen Biotech, a California-based clinical-stage company developing natural killer (NK) cell-based therapies, has announced a strategic partnership with Tokyo-based HekaBio to introduce its SNK01 NK cell therapy in Japan.
Health Technology Insights: Meditology Launches AI SafeGuard for GenAI Security
This alliance allows NKGen to expand its international footprint while leveraging HekaBio’s local regulatory expertise and commercialization capabilities. The partnership aims to accelerate patient access to NKGen’s lead candidate, currently being studied for neurodegenerative and oncologic conditions.
“We are thrilled to partner with HekaBio to bring our innovative NK cell therapy to patients in Japan,” said Paul Song, MD, CEO of NKGen Biotech. “Their deep understanding of the Japanese market and strong relationships with key stakeholders make them an ideal partner.”
Health Technology Insights: Samsung Bioepis, Harrow Partner on Eye Biosimilars in U.S.
As part of the agreement, HekaBio will manage development, clinical operations, and potential commercialization of SNK01 in Japan. The therapy uses expanded and activated NK cells from a patient’s own blood and has shown potential in early-stage studies to enhance immune response and reduce inflammation.
“We are proud to collaborate with NKGen in their mission to deliver novel therapies,” said Rob Claar, CEO of HekaBio. “This partnership aligns perfectly with our commitment to advancing cell and gene therapies in Japan.”
This collaboration supports NKGen’s broader strategy to bring its platform to global markets and meet growing demand for cellular immunotherapies.
Health Technology Insights: Lyra Health Acquires Bend Health, Expanding Whole Family Mental Health Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- GlobeNewswire
